Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 6, Issue 4, 2006, Pages 301-305

  Suppiah, Revathi ^a   Srkalovic, J Gordan ^a   Hussein, Mohamad A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CC 4047; Chemotherapy; Lenalidomide; Plasma cell dyscrasia; Toxicity; Venous thromboembolic disease

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; PLACEBO; PREDNISONE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VINCRISTINE; WARFARIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANXIETY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EMBOLISM PREVENTION; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; HYPERCOAGULABILITY; IMMUNOMODULATION; INCIDENCE; LEG CRAMP; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PLASMA CELL; PNEUMONIA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; STEM CELL TRANSPLANTATION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; VENOUS THROMBOEMBOLISM; IMMUNOLOGY; METABOLISM; PATHOLOGY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 33645090967     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.004     Document Type: Review

References (35)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330:484-489.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
3. Monconduit M, Le Loet X, Bernard JF, et al. Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma. Br J Haematol 1986; 63:599-601.
4. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-1356.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-97.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
7. Fermand JP, Ravaud P, Katsahian S, et al. High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999; 94(suppl 1):396a.
8. Barlogie B, Kyle RA, Anderson KC, et al. Comparable survival in multiple myeloma (MM) with high-dose therapy (HDT) following mel 140 mg/m2 + TBI 12 by autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup trial S9321. Blood 2003; 102:42a.
9. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755-3759.
10. Hussein M. Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Leukemia 2004; 18:893.
11. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
12. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607-618.
13. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
14. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892.
15. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323.
16. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
17. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodys-plastic syndromes. Blood 2001; 98:958-965.
18. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-322.
19. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9:1625-1630.
20. Anderson KC. Multiple myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001; 38:6-10.
21. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-2950.
22. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
23. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263-271.
24. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17:41-44.
25. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2:927-937.
26. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269-3276.
27. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.
28. Zangari M, Tricot, G, Zeldis, J, et al. Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 2001; 98:3226a.
29. Weber D, Chen C, Niesvizky R, et al. A multicenter, randomized, parallel-group, double-blind, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Presented at: the 10th International Myeloma Workshop; April 10-14, 2005; Sydney, Australia. Abstract #738.
30. Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558-566.
31. Weber D. IMiDs-Results of phase III studies in relapsed/refractory myeloma. Paper presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17,2005; Orlando, FL.
32. Hussein MA, Karam M, Brand C, et al. Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and revlimid (R) (DVd-R) a phase I/II trial in advanced relapsed/refractory multiple myeloma (MM) patients. Blood 2004; 104:208.
33. Rajkumar SY, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050-4053.
34. Baz R, Li L, Kotke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycine-based chemotherapy for multiple myeloma. Mayo Clinci Proc 2005; 80:1568-1574.
35. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126:715-721.